Yuria-Pharm is the leading manufacturer of solutions for infusion in Ukraine and former CIS countries. The company supplies medical facilities with more than 100 items of blood- and plasma substitute solutions, original infusion drugs, antibiotics, fungicidal drugs, syrups, antiseptics, parenteral nourishment preparations, parenteral anti-tuberculosis drugs, syringes, I.V. sets.
Founded in 1998, «YURiA-PHARM» focused its efforts on the production of infusions and as of today is a leading infusion manufacturer not only in Ukraine but also in CIS. They supply medical facilities with more than 100 items of blood- and plasma substitute solutions, original infusion drugs, antibiotics, fungicidal drugs, syrups, antiseptics, parenteral nourishment preparations, anti-tuberculosis drugs, syringes, I.V. sets. Their product line sums up to more than 40 infusions, completely covering the needs of medical facilities in infusion therapy. The annual turnover of the company exceeds 60 mln bottles.
«YURiA-PHARM» confidently takes the leading position in the export markets. They deliver their products to Russia, Moldova, Kazakhstan, Uzbekistan, Azerbaijan, Tajikistan, Kirgizia, Turkmenistan, and Georgia. More than 100 items are now being registered for usage in different countries and the number is continuously growing. In 2008 «YURiA-PHARM» Corporation has received a Certificate of compliance to international quality management standards ISO 9001 (9001:2009). In 2011 «YURiAPHARM » Corporation has completed GMP certification. «YURiA-PHARM» total headcount is constantly growing and at the moment exceeds 800, 2/3 of them being involved in production and R&D.
Their company produces a number of preparations (original and generic), which are not produced in CIS countries – REOSORBILACT®, SORBILACT®, DECASAN®, HOROSTEN® etc. For instance, REOSORBILACT® (30% of the total distribution of the preparations included in B 05 ATC code (B05 - Blood substitutes and perfusion solutions) and SORBILACT® constitute a basis of infusion therapy in Ukraine. They have completely replaced polyvinylpyrrolidone preparations (such as Hemodez, Neohemodez, etc.) prohibited in many European and other countries, and restricted dextran preparations. In their portfolio, they also have unique cosmetological treatments – HYALUAL® (an anti-age therapy, helps keep skin young and healthy for a long time), cartilage modifying injectable drug – HYALUAL®-ARTRO – unique innovative cartilage protective preparation of new generation. It is an effective combination of hyaluronic acid and sodium succinate for the treatment of osteoarthrosis.